Handelsavisen
prelaunch
Companies Healthcare PGFF.PK
PG
PGFF.PK OTC Healthcare Facilities & Services

Pgff.Pk

$0,51
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-4 205,9 %
ROE
65,9 %
Net margin
-4 342,0 %
Debt / equity
-0,98
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

PGFF.PK operates in the healthcare sector, specifically in the pharmaceuticals activity, and generates revenue through the provision of healthcare facilities and services.

Business. PGFF.PK operates in the healthcare sector, specifically in the pharmaceuticals activity, and generates revenue through the provision of healthcare facilities and services.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
65,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PGFF.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PGFF.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    PGFF.PK operates in the healthcare sector, specifically in the pharmaceuticals activity, and generates revenue through the provision of healthcare facilities and services.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    PGFF.PK exhibits a severely strained capital structure, with total liabilities of $1.2 billion and total equity of -$612.2 million, resulting in a negative debt-to-equity ratio of -0.98. The company's liquidity position is extremely weak, as evidenced by a current ratio of 0.03 and only $630 in cash and equivalents. The negative operating and free cash flows of -$348.8 million and -$394.3 million, respectively, further underscore the company's inability to generate cash from operations.

    Profitability metrics are deeply negative, with a net loss of -$403.4 million and an operating loss of -$390.7 million. The return on assets of -6.81% indicates that the company is not generating returns from its asset base. The return on equity of 65.89% is misleading due to the negative equity base, and should not be interpreted as a positive performance indicator.

    The company's revenue is not segmented by geographic region or business line in the available data, making it difficult to assess revenue concentration or diversification. The lack of segment data also limits the ability to evaluate the performance of different parts of the business.

    The company's growth trajectory is not clearly defined due to the absence of historical revenue data and forward-looking guidance. The negative operating and free cash flows suggest a lack of financial flexibility and potential operational challenges.

    The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, highlighting the need for close monitoring of its liquidity and capital structure. The low dilution risk suggests that the company is not currently issuing shares at a rate that would significantly dilute existing shareholders.

    Recent events and filings are not detailed in the available data, limiting the ability to assess the company's recent performance and strategic direction. The absence of recent transcripts or filings makes it difficult to evaluate management's outlook or any material developments.

    Key takeaways
    • PGFF.PK has a severely negative net income and operating income, indicating significant financial distress.
    • The company's liquidity position is extremely weak, with a current ratio of 0.03 and minimal cash reserves.
    • The return on equity is misleadingly high due to the negative equity base and should not be interpreted as a positive performance metric.
    • The company's capital structure is highly leveraged, with total liabilities exceeding total assets.
    • There is a lack of segment and geographic data, making it difficult to assess the company's diversification and risk exposure.
    • The company's growth trajectory is unclear due to the absence of historical revenue data and forward-looking guidance.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,51
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$612.2k
    Net cash
    -$599.7k
    Current ratio
    0.0
    Debt / equity
    -1.0
    ROA
    -68.1%
    ROE
    65.9%
    Cash conversion
    86.0%
    CapEx / revenue
    -7.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-4 205,9 %Bottom quartile
    Net Margin-4 342,0 %Bottom quartile
    ROE65,9 %Best in class
    Capex / Rev-7,0 %Above median
    D/E-0,98Best in class
    Cash Conv0,86Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • PGFF.PK Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PGFF.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage